VivoSeq
Cardiovascular

Pericarditis

18

Pipeline Programs↗

8

Active Trials↗

9

Companies Involved↗

Pericarditis is an emerging landscape with 18 programs across 9 companies. The most active players are Cardiol Therapeutics Inc., Kiniksa Pharmaceuticals International, plc, Zomagen Biosciences Ltd.. 5 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

76/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cardiol Therapeutics Inc.

1 program

Phase 2K

Kiniksa Pharmaceuticals International, plc

1 program

Phase 2Z

Zomagen Biosciences Ltd.

1 program

Phase 2K

Kiniksa Pharmaceuticals (UK), Ltd.

2 programs

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3Bayer logo

Bayer

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

14 of 17 classified programs — the dominant modality here.

18%ALL OTHERSRNA therapy212%Protein / enzyme16%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed13 · 48%
Recruiting6 · 22%
Terminated3 · 11%
Unknown status2 · 7%
Active, not recruiting1 · 4%
Not yet recruiting1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

27 trials

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
Recruiting·ZZomagen Biosciences Ltd.·Phase 2·NCT06836232·50 enrolled
Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis
Recruiting·—·N/A·NCT06071156·20 enrolled
High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
Recruiting·UUniversity of Cape Town·Phase 2·NCT04521803·60 enrolled
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
Recruiting·KKiniksa Pharmaceuticals International, plc·Phase 2/3·NCT07010159·165 enrolled
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
Recruiting·CCardiol Therapeutics Inc.·Phase 3·NCT06708299·110 enrolled
A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies
Recruiting·KKiniksa Pharmaceuticals International, plc·Phase 2·NCT07288216·80 enrolled
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
Active, not recruiting·—·Phase 3·NCT05673902·17 enrolled
Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children
Not yet recruiting·—·Phase 3·NCT05805930·48 enrolled
Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
Completed·CCardiol Therapeutics Inc.·Phase 2·NCT05494788·27 enrolled
Study of Colchicine to Treat Acute Pericarditis and Prevent Recurrences
Completed·AAzienda Sanitaria Locale 3, Torino·Phase 3·NCT00128453·240 enrolled
Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment.
Completed·AAzienda Sanitaria Locale 3, Torino·Phase 4·NCT00235079·240 enrolled
Post-Ablation Pericarditis Reduction Study
Completed·—·Phase 2·NCT04906720·248 enrolled
AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)
Completed·—·Phase 4·NCT02219828·21 enrolled
Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode)
Completed·AAzienda Sanitaria Locale 3, Torino·Phase 3·NCT00128414·120 enrolled
A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis
Completed·UUniversity of Cape Town·Phase 3·NCT00810849·1,400 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)